Jenrin Aims to Resurrect CB-1 Antagonists By Simply Avoiding the Brain
This article was originally published in Start Up
Executive Summary
Jenrin was founded on the idea that adverse psychiatric effects didn't necessarily spell a drug's doom, especially if the medicine did not need to get into the brain in the first place. By tweaking the molecules to prevent their transport across the blood-brain barrier and other physiological hurdles, he hoped to resurrect a number of molecules with potential utility in diseases ranging from dyslipidemia to bowel dysfunction.